Look for approval of IONS SMA drug in both the US and the EU very soon. Also, there is really nothing to treat really high level of triglycerides. With IONS ApoC III inhibitor look for an approval of that drug for the two orphan indications. For a bigger populations for just elevated triglycerides that will take time. But within three years IONS should be grossing over a billion a year. By that time their 2.5 generation LICA form Lp(a) drug could also very well be approved. IMO by then the company should be given a P/E of at least 30. t
This is kind of a cool set up as long as Y keeps it going. Skybusted lost huge on PTLA and they got an FDA letter and no approval. Things will really start flying for IONS over the next 12 months. t
I can only get to this message board using my iPhone, but that is better than nothing and top shelf might ever find out about it. 😆
Cameron loves walking! He is even learning to kick a ball! He gets an injection this week in the clinical trial. He continues to impress us with his strength and we know the doctors will be as impressed when we see them this week. While we are there we are taking him to Sea World! Let's hope we all stay healthy!!!!!!!!
Looking forward to SMA drug approval. t
Juno Therapeutics receives notice from the FDA that a clinical hold has been placed on the Phase II clinical trial of JCAR015 (shares halted) (40.85 +0.88)
The co announced that it has received notice from the U.S. Food and Drug Administration (FDA) that a clinical hold has been placed on the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL), known as the "ROCKET" trial. The clinical hold was initiated after two patient deaths last week, which followed the recent addition of fludarabine to the pre-conditioning regimen.
Juno has proposed to the FDA to continue the ROCKET trial using JCAR015 with cyclophosphamide pre-conditioning alone. In response, the FDA has requested that Juno submit, as a Complete Response to the Clinical Hold: a revised patient informed consent form, a revised investigator brochure, a revised trial protocol, and a copy of the presentation made to the agency yesterday. Juno will submit the requested information to the FDA this week.
Juno's trials and plans for its other CD19-directed CAR-T cell product candidates, including JCAR017, are not affected.
This type of "info" that you "release" here show's exactly how you have been exposed as a person with really no info. I believe that deep down you are afraid that IONS is going to make it really big and you have now gone on the war path against it. NO??? Everyone take a look at your "timely" post about what type of tough straights BIIB is in and how terrible they are going to do and how bad their MS drugs are doing and then go look up their share price today to see UP OVER $50 today. You might want to look at your own shoes before you lecture someone about deep doo doo. And people here can thank you for the "tip" on BIIB. t
Check again SFB's and maybe put up the last quote for each company in regards to share price. I myself wouldn't brag about a one day movement as the market is complicated and many things go on over a day's worth of trading. It is really the intermediate and long term that matters. But since you are a SFB's that brought up the issue....why don't you put out the closing price of each stock? Frankly if I had recommended a stock that took a reverse stock split of 10:1 I'd never show my face here again, or at least not brag....but you're a different kind of animal. t
Again an exaggeration by you and you are fixated on old news. And please pull up the link to back up your delusion. Why don't you go after that oil analysts at Goldman Sachs that four years ago said oil was going to $200 per barrel? You have no ability to think in the abstract. Skybuster00, carry on captain!!t
WOW you really wigged out......no sound arguments. You need to change your name to skybuster00 to reflect your true knowledge!!!! t
Also, why don't you tell the full story. 75% of GILD success has occurred over the last two years with their blockbuster HepC drugs. They however have really strained the medical system with that huge price to be paid for so many people who have Hep C. The other real truths are that the drug was priced so high that they have been forced to discount it to the VA and other insurances companies. The other disgusting thing about that was that if you live in India you can get full treatment with their Hep C drug for $900.......how about maybe pointing that out??? Also, the market isn't too impressed about GILD lately. That being that there are questions about their being able to keep that monetary projection into the future with new products....how about pointing that out?? Also, ARIA, IDRA, VRTX, EXEL and many others started at the same time or around the same time as IONS did. How about pointing that out? How about a comparison of IDRA with IONS in regards to: cash on hand, deals with big pharma, pipeline etc??? I would rather take my chances with a company that hasn't had their value fully reflected than to go with GILD. Though GILD is not a bad investment here. The main question is, do they have the potential that IONS has over the next three years? I say NO. Especially when my genius from skybuster gets over to their website and the company and scorches them for their extremely high prices and price differentials between countries for the Hep C drugs, their lack of diversity of pipeline making it where analysts are demanding they do something or buy something because of this fear. t
I'd immediately set out ot the GILD board and chastise them about the cost fo their medication and how you are afraid that we will run out of money with their charging orphan drug prices for a mainstream illness. t
You must be talking to Aaron Reames....wasn't my call. You seem to be getting weirder and weirder. Also hint at being...won't say on this screen but what you said about the SMN drug, the patient's, and the judgmental statement was somewhat frightening. Maybe you could call that Aaron guy and tutor him on how to be perfect. t
Why don't you write up your speech and present it the AWRW board where millions have HepC and the price of the drug will probably like the ones are now.....that being orphan drug pricing for a main stream disease. t
Ten cent, I think those numbers that you noted could very well be representative what we will see from this med. I just get the feeling that the EU will approve this message before we see the FDA here do it. t
Man you need to go to the ARWR board and lecture them about HepC and the cost and all that you've done here. t
Again you don't understand medicine. It will be cost effective to treat these babies with a medication that can greatly decrease their need for hospitalization. A two week hospital stay on a ventilator will be more expensive that a year's cost of his medication. Why don't you make about 100K enemies and tell your great knowledge to the FAST organization. t
The guy doesn't understand medicine....If he had a child with that disease he'd learn quickly. But for now to try and make a worse argument toward IONS he resorts to that. t
Bad arguments so you question my being here? How about you moving over to the ARWR board permanently?? t